目的分析血清趋化因子C-C-基序配体3(CCL3)、信号肽-CUB-表皮生长因子结构域包含蛋白1(SCUBE1)对髋膝关节置换术后下肢深静脉血栓形成(DVT)的预测价值。方法回顾性选择2022年1月至2024年1月简阳市人民医院行髋膝关节置换术的患者110例...目的分析血清趋化因子C-C-基序配体3(CCL3)、信号肽-CUB-表皮生长因子结构域包含蛋白1(SCUBE1)对髋膝关节置换术后下肢深静脉血栓形成(DVT)的预测价值。方法回顾性选择2022年1月至2024年1月简阳市人民医院行髋膝关节置换术的患者110例为研究对象,根据术后1个月下肢静脉造影结果分为DVT组(48例)和非DVT组(62例)。比较两组临床资料,以及术前、术后1 d CCL3、SCUBE1水平和凝血功能[活化部分凝血活酶时间、凝血酶原时间、纤维蛋白原(FIB)];采用Spearman相关性分析法分析CCL3、SCUBE1与凝血指标的相关性;采用多因素Logistic回归分析髋膝关节置换术后下肢DVT的危险因素;绘制受试者工作特征(ROC)曲线分析CCL3、SCUBE1水平对下肢DVT的预测效能。结果DVT组术后卧床时间≥3 d患者比例高于非DVT组(P<0.05)。术后1 d,DVT组CCL3、SCUBE1、FIB水平升高(P<0.05),且DVT组均高于非DVT组(P<0.05)。Spearman相关性分析显示,CCL3、SCUBE1水平与FIB均呈正相关(r=0.572、0.591,P<0.05)。多因素Logistic回归分析显示,高水平CCL3、SCUBE1、FIB为髋膝关节置换术后下肢DVT的危险因素(P<0.05)。ROC曲线分析显示,CCL3、SCUBE1二者联合预测髋膝关节置换术后下肢DVT的曲线下面积为0.950,高于CCL3(0.891)、SCUBE1(0.879)。结论髋膝关节置换术后下肢DVT患者血清CCL3、SCUBE1水平升高,且二者联合预测下肢DVT的效能更高。展开更多
Background:The prognostic significance of the chemokine receptor CCR7 in diffuse large B-cell lymphoma(DLBCL)has been reported previously.However,the detailed mechanisms of CCR7 in DLBCL,particularly regarding its int...Background:The prognostic significance of the chemokine receptor CCR7 in diffuse large B-cell lymphoma(DLBCL)has been reported previously.However,the detailed mechanisms of CCR7 in DLBCL,particularly regarding its interaction with lenalidomide treatment,are not fully understood.Methods:Our study utilized bioinformatics approaches to identify hub genes in SU-DHL-2 cell lines treated with lenalidomide compared to control groups.Immunohistochemical data and clinical information from 122 patients with DLBCL were analyzed to assess the correlation of CCR7 and p-ERK1/2 expression with the prognosis of DLBCL.Furthermore,in vitro and in vivo experiments were conducted to clarify the role of CCR7 in the response of DLBCL to lenalidomide treatment.Results:Our bioinformatics analysis pinpointed CCR7 as a hub gene in the context of lenalidomide treatment in DLBCL.Notably,31.14%and 36.0%(44/122)of DLBCL cases showed positive expression for CCR7 and ERK1/2 respectively,establishing them as independent prognostic factors for adverse outcomes in DLBCL via multivariate Cox regression analysis.Additionally,our studies demonstrated that the external application of the protein CCL21 promoted proliferation,migration,invasion,and activation of the ERK1/2 pathway in SU-DHL-2 and OCI-LY3 cell lines with high levels of CCR7 expression.This effect was mitigated by CCR7 silencing through siRNA,application of ERK inhibitors,or lenalidomide treatment.In vivo experiments reinforced the efficacy of lenalidomide,significantly reducing tumor growth rate,tumor mass,serum total LDH levels,and expression of CCR7 and p-ERK1/2 in a SUDHL-2 xenograft model in nude mice(p<0.05).Conclusion:Our study clarifies the potential role of the CCL21/CCR7/ERK1/2 axis in the therapeutic effects of lenalidomide in DLBCL treatment.展开更多
文摘目的分析血清趋化因子C-C-基序配体3(CCL3)、信号肽-CUB-表皮生长因子结构域包含蛋白1(SCUBE1)对髋膝关节置换术后下肢深静脉血栓形成(DVT)的预测价值。方法回顾性选择2022年1月至2024年1月简阳市人民医院行髋膝关节置换术的患者110例为研究对象,根据术后1个月下肢静脉造影结果分为DVT组(48例)和非DVT组(62例)。比较两组临床资料,以及术前、术后1 d CCL3、SCUBE1水平和凝血功能[活化部分凝血活酶时间、凝血酶原时间、纤维蛋白原(FIB)];采用Spearman相关性分析法分析CCL3、SCUBE1与凝血指标的相关性;采用多因素Logistic回归分析髋膝关节置换术后下肢DVT的危险因素;绘制受试者工作特征(ROC)曲线分析CCL3、SCUBE1水平对下肢DVT的预测效能。结果DVT组术后卧床时间≥3 d患者比例高于非DVT组(P<0.05)。术后1 d,DVT组CCL3、SCUBE1、FIB水平升高(P<0.05),且DVT组均高于非DVT组(P<0.05)。Spearman相关性分析显示,CCL3、SCUBE1水平与FIB均呈正相关(r=0.572、0.591,P<0.05)。多因素Logistic回归分析显示,高水平CCL3、SCUBE1、FIB为髋膝关节置换术后下肢DVT的危险因素(P<0.05)。ROC曲线分析显示,CCL3、SCUBE1二者联合预测髋膝关节置换术后下肢DVT的曲线下面积为0.950,高于CCL3(0.891)、SCUBE1(0.879)。结论髋膝关节置换术后下肢DVT患者血清CCL3、SCUBE1水平升高,且二者联合预测下肢DVT的效能更高。
基金supported by the Key Research and Development Program of Science and Technology Department of Guizhou Province(No.20204Y147).
文摘Background:The prognostic significance of the chemokine receptor CCR7 in diffuse large B-cell lymphoma(DLBCL)has been reported previously.However,the detailed mechanisms of CCR7 in DLBCL,particularly regarding its interaction with lenalidomide treatment,are not fully understood.Methods:Our study utilized bioinformatics approaches to identify hub genes in SU-DHL-2 cell lines treated with lenalidomide compared to control groups.Immunohistochemical data and clinical information from 122 patients with DLBCL were analyzed to assess the correlation of CCR7 and p-ERK1/2 expression with the prognosis of DLBCL.Furthermore,in vitro and in vivo experiments were conducted to clarify the role of CCR7 in the response of DLBCL to lenalidomide treatment.Results:Our bioinformatics analysis pinpointed CCR7 as a hub gene in the context of lenalidomide treatment in DLBCL.Notably,31.14%and 36.0%(44/122)of DLBCL cases showed positive expression for CCR7 and ERK1/2 respectively,establishing them as independent prognostic factors for adverse outcomes in DLBCL via multivariate Cox regression analysis.Additionally,our studies demonstrated that the external application of the protein CCL21 promoted proliferation,migration,invasion,and activation of the ERK1/2 pathway in SU-DHL-2 and OCI-LY3 cell lines with high levels of CCR7 expression.This effect was mitigated by CCR7 silencing through siRNA,application of ERK inhibitors,or lenalidomide treatment.In vivo experiments reinforced the efficacy of lenalidomide,significantly reducing tumor growth rate,tumor mass,serum total LDH levels,and expression of CCR7 and p-ERK1/2 in a SUDHL-2 xenograft model in nude mice(p<0.05).Conclusion:Our study clarifies the potential role of the CCL21/CCR7/ERK1/2 axis in the therapeutic effects of lenalidomide in DLBCL treatment.
